Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX): $4.78

0.07 (-1.44%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add NVAX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#120 of 363

in industry

NVAX Price/Volume Stats

Current price $4.78 52-week high $11.36
Prev. close $4.85 52-week low $3.53
Day low $4.76 Volume 3,615,175
Day high $4.95 Avg. volume 8,629,920
50-day MA $4.61 Dividend yield N/A
200-day MA $6.34 Market Cap 668.98M

NVAX Stock Price Chart Interactive Chart >

NVAX POWR Grades

  • NVAX scores best on the Value dimension, with a Value rank ahead of 77.51% of US stocks.
  • The strongest trend for NVAX is in Quality, which has been heading down over the past 26 weeks.
  • NVAX ranks lowest in Stability; there it ranks in the 1st percentile.

NVAX Stock Summary

  • NOVAVAX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.87% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.41 for NOVAVAX INC; that's greater than it is for only 4.92% of US stocks.
  • With a year-over-year growth in debt of -49.3%, NOVAVAX INC's debt growth rate surpasses merely 5.16% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to NOVAVAX INC, a group of peers worth examining would be GSIT, MRKR, FULC, BCDA, and CRIS.
  • NVAX's SEC filings can be seen here. And to visit NOVAVAX INC's official web site, go to www.novavax.com.

NVAX Valuation Summary

  • In comparison to the median Healthcare stock, NVAX's price/earnings ratio is 103.43% lower, now standing at -1.
  • NVAX's EV/EBIT ratio has moved up 11.9 over the prior 243 months.

Below are key valuation metrics over time for NVAX.

Stock Date P/S P/B P/E EV/EBIT
NVAX 2023-12-29 0.5 -0.8 -1.0 -0.2
NVAX 2023-12-28 0.6 -0.9 -1.1 -0.3
NVAX 2023-12-27 0.6 -0.9 -1.1 -0.3
NVAX 2023-12-26 0.6 -0.9 -1.1 -0.3
NVAX 2023-12-22 0.6 -0.9 -1.1 -0.3
NVAX 2023-12-21 0.6 -0.9 -1.1 -0.3

NVAX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 1390.08%.
  • The 5 year revenue growth rate now stands at 7.39%.
  • Its 4 year net income to common stockholders growth rate is now at 53.22%.
Over the past 34 months, NVAX's revenue has gone up $1,963,815,000.

The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,981.872 -415.937 -657.939
2022-09-30 1,846.673 -640.529 -1,321.974
2022-06-30 1,290.94 -743.964 -1,475.792
2022-03-31 1,403.032 -428.649 -1,317.624
2021-12-31 1,146.29 322.946 -1,743.751
2021-09-30 1,203.749 536.786 -1,075.031

NVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
  • NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
  • GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.

The table below shows NVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.600 1 -14.595
2021-03-31 0.606 1 -1.737
2020-12-31 0.502 1 -0.781
2020-09-30 0.345 1 -0.602
2020-06-30 0.126 1 -0.222
2020-03-31 0.084 1 -0.295

NVAX Price Target

For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $264.20 Average Broker Recommendation 1.58 (Moderate Buy)

Novavax, Inc. (NVAX) Company Bio


Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.


NVAX Latest News Stream


Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream


Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Smart Shorts: 7 Meme Stocks to Bet Against in 2024

These seven meme stocks have surged as speculators declare "the coast is clear," but a big reversal for each of them may be forthcoming.

Thomas Niel on InvestorPlace | December 28, 2023

3 Heavily Shorted Stocks That Still Won’t See a Squeeze

These are the heavily shorted stocks to avoid as they are likely to continue trending lower on the back of very weak fundamentals.

Faisal Humayun on InvestorPlace | December 25, 2023

Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?

Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?

Yahoo | December 20, 2023

Owning 48% shares,institutional owners seem interested in Novavax, Inc. (NASDAQ:NVAX),

Key Insights Significantly high institutional ownership implies Novavax's stock price is sensitive to their trading...

Yahoo | December 19, 2023

3 Meme Stocks That Could Fade Away in 2024

These are the meme stocks to avoid or sell as they have extremely weak fundamentals and are unlikely to recover from a financial perspective.

Faisal Humayun on InvestorPlace | December 18, 2023

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo -20.60%
3-mo -0.42%
6-mo -33.98%
1-year -28.23%
3-year -97.25%
5-year -56.62%
YTD -0.42%
2023 -53.31%
2022 -92.81%
2021 28.30%
2020 2,701.76%
2019 -89.18%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!